Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy
- PMID: 22972493
- PMCID: PMC3525803
- DOI: 10.1038/gt.2012.71
Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy
Abstract
We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB_RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10(7) vp (virus particles) and an upper plateau of uptake at 10(11) vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10(10) vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10(11) vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.
Conflict of interest statement
No competing financial interests exist
Figures






Similar articles
-
A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.Gene Ther. 2010 Nov;17(11):1325-32. doi: 10.1038/gt.2010.63. Epub 2010 Apr 29. Gene Ther. 2010. PMID: 20428214 Free PMC article.
-
A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.Cancer Gene Ther. 2012 Dec;19(12):839-44. doi: 10.1038/cgt.2012.68. Epub 2012 Oct 5. Cancer Gene Ther. 2012. PMID: 23037808 Free PMC article.
-
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27. Gene Ther. 2016. PMID: 26814609 Free PMC article.
-
A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy.Curr Gene Ther. 2002 Dec;2(4):393-402. doi: 10.2174/1566523023347599. Curr Gene Ther. 2002. PMID: 12477251 Review.
-
Radiovirotherapy: principles and prospects in oncology.Curr Pharm Des. 2012;18(22):3313-20. doi: 10.2174/1381612811209023313. Curr Pharm Des. 2012. PMID: 22397732 Review.
Cited by
-
Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.Mol Ther. 2016 Aug;24(8):1395-404. doi: 10.1038/mt.2016.95. Epub 2016 May 9. Mol Ther. 2016. PMID: 27157666 Free PMC article.
-
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.Mol Ther Oncolytics. 2023 Apr 10;29:44-58. doi: 10.1016/j.omto.2023.04.001. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37180034 Free PMC article.
-
Designing and building oncolytic viruses.Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31. Future Virol. 2017. PMID: 29387140 Free PMC article. Review.
-
EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene.Mol Ther Nucleic Acids. 2013 Nov 5;2(11):e131. doi: 10.1038/mtna.2013.58. Mol Ther Nucleic Acids. 2013. PMID: 24193032 Free PMC article.
-
Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.BMC Cancer. 2014 Apr 30;14:303. doi: 10.1186/1471-2407-14-303. BMC Cancer. 2014. PMID: 24884806 Free PMC article. Review.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.[Erratum appears in CA Cancer J Clin, 2011 Mar–Apr;61(2):134] CA Cancer J Clin. 2011;61(2):69–90. - PubMed
-
- Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol. 2004;69(1–3):101–17. - PubMed
-
- McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130–41. - PubMed
-
- Yamamoto M, Curiel DT. Cancer gene therapy. Technol Cancer Res Treat. 2005;4(4):315–30. - PubMed
-
- Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta. 1993;1154(1):65–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases